関連する実験動画
Updated: Jun 17, 2026

07:54
Cholesterol Efflux Assay
Published on: March 6, 2012
主要高コレステロール血症の785人の患者でセリバスタチンによるC反応性タンパク質の急速な減少
P M Ridker1, N Rifai, S P Lowenthal
1Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA 02115, USA. pridker@partners.org
Circulation
|March 10, 2001
まとめ
セリバスタチンは,高コレステロール血症の患者のC反応性タンパク質 (CRP) レベルを8週間以内に有意に低下させた. このCRPの減少は,LDLコレステロールまたはHDLコレステロールレベルの変化とは無関係でした.
科学分野:
- 心血管医学 心血管医学
- 薬理学 薬理学とは
背景:
- セリバスタチンを含むスタチンは,C反応性タンパク質 (CRP) のレベルを低下させることが知られている.
- スタチンが誘発したCRP低下の速度,一般化,および用量反応に関する不確実性があります.
研究 の 目的:
- セリバスタチンがCRPレベルに及ぼす効果を調査する.
- セリバスタチンによるCRP減少が投与量に依存し,脂質の変化と相関するかどうかを判断する.
主な方法:
- 一次性高コレステロール血症の患者785人を対象とした研究.
- CRP,LDLコレステロール (LDL-C) およびHDLコレステロール (HDL-C) の測定は,ベースラインおよび8週間後に行われます.
- セリバスタチンの0.4mgまたは0.8mgの治療.
主要な成果:
- セリバスタチンは,中位CRPを13.3%,中位CRPを24.5% (P<0.001) 減少させた.
- LDL-Cは用量に依存して減少したが,CRPの減少に対する明確な用量反応は観察されなかった.
- CRPの変化とLDL-CまたはHDL-Cの変化との間に有意な相関は見つかりませんでした.
結論:
- セリバスタチン治療は,原発性高コレステロール血症の患者で8週間以内にCRPレベルを効果的に低下させます.
- 観察されたCRPの低下は,脂質低下効果とは無関係です.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

